HMNC Brain Health Announces Publication of Ketabon (KET01) Clinical Trial Results in JAMA Network Open

Oral prolonged-release ketamine formulation (KET01) demonstrates minimal dissociation and cardiovascular effects with early antidepressant ...

AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder

Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized ...
Zacks Investment Research on MSN

Ataibeckley completes VLS-01 dosing in Phase IIb depression study

AtaiBeckley ATAI announced the completion of dosing the last patient in the phase IIb Elumina study evaluating VLS-01 for ...
Pharmabiz

AtaiBeckley doses last patient in Elumina, phase 2b trial of VLS-01 in adults with treatment-resistant depression

AtaiBeckley doses last patient in Elumina, phase 2b trial of VLS-01 in adults with treatment-resistant depression: New York Tuesday, July 7, 2026, 10:00 Hrs [IST] AtaiBeckley Inc.

AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs

ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on ...
Nasdaq

Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders

Calgary, Alberta--(Newsfile Corp. - February 18, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), is pleased to announce that it is receiving advisory services and funding from the ...